Arinna Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 15.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 13.06 Cr
as on 23-10-2024
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 Cr
as on 23-10-2024
- Satisfied Charges ₹ 3.15 Cr
as on 23-10-2024
- Revenue 18.53%
(FY 2023)
- Profit 35.33%
(FY 2023)
- Ebitda -75.75%
(FY 2023)
- Net Worth 12.35%
(FY 2023)
- Total Assets -6.68%
(FY 2023)
About Arinna Lifesciences
The Corporate was formerly known as Arinna Lifesciences Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 15.00 Cr and a paid-up capital of Rs 13.06 Cr.
The company currently has active open charges totaling ₹3.00 Cr. The company has closed loans amounting to ₹3.15 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Arinna Lifesciences Limited India are Subramaniam Iyer as CFO and Smit Rupareliya as Company Secretary. Siddharth Shah, Shankar Gopalakrishnan, Vivek Seth, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24230GJ2013PLC076619
- Company No.
076619
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
29 Aug 2013
- Date of AGM
29 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Arinna Lifesciences Limited offer?
Arinna Lifesciences Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Antiepileptic Drugs, Pharma Ingredients & Raw Materials, Nervous System and Antipsychotic API, Psychotherapeutic Agents, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules.
Who are the key members and board of directors at Arinna Lifesciences?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vivek Seth  | Managing Director | 29-Aug-2013 | Current |
| Subramaniam Iyer | CFO | 17-May-2022 | Current |
| Smit Rupareliya | Company Secretary | 24-Apr-2024 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Siddharth Shah | Director | 23-Apr-2015 | Current |
| Rohit Mantri | Nominee Director | 03-May-2016 | Current |
| Shankar Gopalakrishnan | Director | 23-Apr-2015 | Current |
| Shilpa Seth | Director | 29-Aug-2013 | Current |
Financial Performance and Corporate Structure Insights of Arinna Lifesciences.
Arinna Lifesciences Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.53% increase. The company also saw a substantial improvement in profitability, with a 35.33% increase in profit. The company's net worth Soared by an impressive increase of 12.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arinna Lifesciences?
In 2023, Arinna Lifesciences had a promoter holding of 37.27% and a public holding of 62.73%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Symbiotec Pharmalab Private LimitedActive 22 years 3 monthsShankar Gopalakrishnan and Rohit Mantri are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 01 Apr 2021 | ₹3.00 Cr | Open |
Axis Bank Limited Creation Date: 26 Feb 2018 | ₹3.15 Cr | Satisfied |
How Many Employees Work at Arinna Lifesciences?
Arinna Lifesciences has a workforce of 401 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arinna Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arinna Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
